Stallion India Fluorochemicals Ltd. (STALLION.NS)
Mumbai, IN
Stallion India Fluorochemicals Limited focuses on the aggregation, blending, and refinement of various refrigerants and industrial gases across India. The company supplies a diverse range of fluorochemicals, encompassing hydrocarbons (HC), hydrofluorocarbons (HFC), and hydrofluoroolefins (HFO). Furthermore, they provide essential equipment and replacement parts for the air conditioning and refrigeration (AC&R) industry, such as pressure washers and vacuum pumps. Their product portfolio also includes consumer-sized aerosol cans of refrigerants like R290, R-134a, R-600a, and other hydrocarbons, in addition to paints. A comprehensive selection of refrigerants and fluorine compounds is available, featuring HFOs, various blends, HFCs and their combinations, hydrocarbons, blowing agents, propellants, electrical insulating substances, and fire extinguishants. They also offer specialized gases for semiconductor and electronics applications, including CF4 and SF6. Stallion India Fluorochemicals caters to a wide array of sectors, including air conditioning and refrigeration, fire suppression, semiconductor manufacturing, automotive production, pharmaceuticals and medical, glass bottling, aerosol packaging, defense, gas-insulated substations, and spray foam industries. Established in 1992, the company maintains its headquarters in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.00% | +2.97% | +15.47% | +35.55% | +2.66% | -26.36% | +119.62% | +37.70% | +37.70% | +37.70% | +37.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%+14.1% ★ Q1'26: -27.4% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+30.9% ★ Q1'26: -20.4% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+10.5% Q1'26: +12.6% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+13.1% ★ Q1'26: +14.3% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+14.9% ★ Q1'26: +14.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+3.5% Q1'26: +3.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.60× ★ Q1'26: 0.53× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Geetu Yadav | Executive Director | — | female |
| Govind Rao | Company Secretary & Compliance Officer | — | male |
| Manisha Shazad Rustomji | Executive Director | — | female |
| Rohan Shazad Rustomji | Executive Director | — | male |
| Shazad Sheriar Rustomji | Chairman, MD & Chief Executive Officer | — | male |
| Virenderkumar Mehta | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for STALLION.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
